What is the appropriate evaluation and management of amenorrhea?

Evaluation and Management of Amenorrhea

Initial Diagnostic Approach

All patients presenting with amenorrhea—whether primary (no menarche by age 15 or 3 years post-thelarche) or secondary (cessation of regular menses for 3 months or irregular menses for 6 months)—must first undergo pregnancy testing, followed by measurement of FSH, LH, prolactin, and TSH to categorize the underlying etiology. 1, 2, 3

Key Historical Elements to Elicit

• Menstrual timeline: Age of thelarche, menarche timing, and previous menstrual patterns 2
• Weight and nutrition: Recent weight changes, eating patterns, restrictive dieting, and exercise intensity (screen for functional hypothalamic amenorrhea and eating disorders) 2, 4
• Medication exposure: Hormonal contraceptives, antipsychotics, chemotherapy 2
• Symptom clusters: Galactorrhea (hyperprolactinemia), hot flashes/night sweats (ovarian insufficiency), hirsutism/acne (hyperandrogenism/PCOS), headaches/visual changes (pituitary pathology) 2, 5
• Chronic illness: Thyroid disease, autoimmune conditions, malignancy 2, 4

Physical Examination Priorities

• Pubertal staging: Tanner staging to distinguish between hypogonadotropic and hypergonadotropic causes 6, 7
• Anthropometrics: Height, weight, BMI trends, and growth velocity 2
• Hyperandrogenic signs: Hirsutism, acne, clitoromegaly 2, 5
• Anatomic assessment: Presence of uterus and vagina, imperforate hymen, vaginal septum 3, 6
• Dysmorphic features: Webbed neck, shield chest, short stature (Turner syndrome) 3, 7

---

Laboratory Evaluation Algorithm

First-Tier Testing (All Patients)

• Urine or serum β-hCG (exclude pregnancy) 1, 2, 3
• Serum FSH and LH 1, 2, 3, 5
• Serum prolactin 1, 2, 3, 5
• Serum TSH 1, 2, 3, 5

Interpretation-Driven Second-Tier Testing

Elevated FSH (>25–40 IU/L): Indicates primary ovarian insufficiency 8, 2, 3

• Obtain karyotype to identify Turner syndrome (45,X) or mosaicism 8, 3, 7
• Test for fragile X premutation (FMR1 gene) in all women with POI, with pre-test counseling regarding implications for offspring 8
• Screen for 21-hydroxylase antibodies (21OH-Ab) or adrenocortical antibodies (ACA) to detect autoimmune adrenal insufficiency; if positive, refer to endocrinology for adrenal function testing and Addison's disease evaluation 8

Low or normal FSH with elevated prolactin (>25 ng/mL): Suggests hyperprolactinemia 2, 3, 5

• Obtain brain MRI with pituitary protocol to evaluate for prolactinoma or other sellar/suprasellar masses 2, 3
• Review medications (antipsychotics, metoclopramide, opioids) 2

Low or normal FSH and LH with normal prolactin and TSH: Suggests hypothalamic or polycystic ovary syndrome 2, 3

• Measure serum androgens (total testosterone, DHEA-S, 17-hydroxyprogesterone) if clinical hyperandrogenism or irregular cycles suggest PCOS 2, 3, 5
• Consider pelvic ultrasound to assess ovarian morphology and endometrial thickness 2, 3
• Evaluate for functional hypothalamic amenorrhea: assess energy availability, exercise volume, psychosocial stressors, and eating disorder screening 2, 4

Primary amenorrhea with absent uterus on exam: Obtain karyotype and serum testosterone 3, 6

• 46,XY with elevated testosterone: androgen insensitivity syndrome 3, 6
• 46,XX with normal female testosterone: Müllerian agenesis (Mayer-Rokitansky-Küster-Hauser syndrome) 3, 6

---

Etiology-Specific Management

Premature Ovarian Insufficiency (POI)

Women with POI and migraine with aura should receive transdermal 17β-estradiol (50–100 µg/24 hours) rather than oral estrogen, due to lower thrombotic risk. 9 This recommendation from the European Society of Human Reproduction and Embryology extends the guidance for hypertensive women with POI to those with migraine with aura 9.

• Hormone replacement therapy: Initiate transdermal 17β-estradiol 50–100 µg/24 hours with cyclic progestogen (medroxyprogesterone acetate 10 mg daily for 12–14 days/month or micronized progesterone 200 mg daily for 12–14 days/month) in women with intact uterus 8, 9
• Duration: Continue HRT until at least age 51 (average age of natural menopause) 8, 9
• Contraception counseling: Women with POI retain 5–10% residual ovulation capacity; discuss contraception if pregnancy is not desired 8, 9
• Bone health: Screen for osteoporosis with DEXA scan; adequate calcium (1200 mg/day) and vitamin D (800–1000 IU/day) supplementation 8, 4
• Cardiovascular surveillance: Monitor blood pressure, lipids, and metabolic parameters annually 8, 9
• Fertility options: Refer to reproductive endocrinology for oocyte donation counseling 8, 7
• Monitoring: Annual assessment of blood pressure, weight, smoking status, symptom control, and migraine patterns if applicable 9

Functional Hypothalamic Amenorrhea

• Address underlying cause: Nutritional rehabilitation for eating disorders, reduction of excessive exercise, stress management 2, 4
• Bone density assessment: Obtain DEXA scan; functional hypothalamic amenorrhea causes significant bone loss that may be irreversible 2, 4
• Hormone replacement: Consider transdermal estradiol with cyclic progestogen if behavioral interventions fail and bone density is compromised 2
• Multidisciplinary care: Involve nutrition, psychology, and sports medicine as appropriate 2, 4

Polycystic Ovary Syndrome (PCOS)

• Metabolic screening: Fasting glucose, 2-hour oral glucose tolerance test, lipid panel to assess for metabolic syndrome and type 2 diabetes risk 2, 3
• Endometrial protection: Cyclic progestogen (medroxyprogesterone acetate 10 mg for 10–14 days every 1–3 months) or combined oral contraceptives to prevent endometrial hyperplasia and cancer 2, 3
• Lifestyle modification: Weight loss of 5–10% improves metabolic and reproductive outcomes 2, 3
• Fertility management: Refer to reproductive endocrinology if pregnancy desired 2

Hyperprolactinemia

• Dopamine agonist therapy: Cabergoline (0.25–1 mg twice weekly) or bromocriptine (2.5–15 mg daily) for prolactinomas or idiopathic hyperprolactinemia 4, 5
• Neurosurgical referral: For macroadenomas with mass effect or dopamine agonist resistance 4
• Serial MRI: Monitor tumor size in patients on medical management 4

Anatomic Abnormalities

• Imperforate hymen or transverse vaginal septum: Surgical correction 3, 6
• Müllerian agenesis: Vaginal dilator therapy or surgical neovagina creation; psychological support; refer to reproductive endocrinology for surrogacy counseling 3, 6
• Androgen insensitivity syndrome: Gonadectomy after completion of puberty (due to malignancy risk); estrogen replacement; psychological support 3, 6

---

Critical Pitfalls to Avoid

• Assuming infertility in POI: Women with POI maintain unpredictable ovarian function and can conceive spontaneously; do not withhold contraception counseling 8, 9, 3
• Delaying bone density assessment: Functional hypothalamic amenorrhea and POI cause rapid, potentially irreversible bone loss; obtain DEXA early 2, 4
• Overlooking autoimmune adrenal insufficiency: Screen all POI patients for 21OH-Ab/ACA; undiagnosed Addison's disease is life-threatening 8
• Using oral estrogen in migraine with aura: Transdermal 17β-estradiol is mandatory due to thrombotic risk; oral formulations are contraindicated 9
• Missing Turner syndrome variants: Karyotype all patients with elevated FSH, even with normal stature or phenotype; mosaicism is common 8, 3, 7
• Neglecting endometrial protection in PCOS: Chronic anovulation increases endometrial cancer risk; ensure regular withdrawal bleeds 2, 3